<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre=": italic;} PathogensPathogenspathogensPathogens2076-0817MDPI pmcid: 7400054 doi: 10.3390/pathogens9070519pathogens-09-00519 : Review Coronavirus" exact="Disease" post="Pandemic (COVID-19): Challenges and a Global Perspective https://orcid.org/0000-0002-2832-4854MalikYashpal Singh1*https://orcid.org/0000-0002-3326-5465KumarNaveen2https://orcid.org/0000-0002-1947-4463SircarShubhankar1https://orcid.org/0000-0002-6489-6913KaushikRahul3BhatSudipta1https://orcid.org/0000-0001-7469-4752DhamaKuldeep4*GuptaParakriti5GoyalKapil5SinghMini"/>
 <result pre="with a major threat to humankind, represented by the coronavirus" exact="disease" post="(COVID-19) pandemic, caused by the severe acute respiratory syndrome,"/>
 <result pre="by the coronavirus disease (COVID-19) pandemic, caused by the severe" exact="acute" post="respiratory syndrome, coronavirus-2 (SARS-CoV-2). As of now, COVID-19 has"/>
 <result pre="the coronavirus disease (COVID-19) pandemic, caused by the severe acute" exact="respiratory" post="syndrome, coronavirus-2 (SARS-CoV-2). As of now, COVID-19 has affected"/>
 <result pre="much faster than its two ancestors, SARS-CoV and Middle East" exact="respiratory" post="syndrome-CoV (MERS-CoV), but has low fatality rates. Our analyses"/>
 <result pre="prone to serious clinical outcomes, which may be associated with" exact="acute" post="respiratory distress syndrome (ARDS) and cytokine storm. The cohesive"/>
 <result pre="to serious clinical outcomes, which may be associated with acute" exact="respiratory" post="distress syndrome (ARDS) and cytokine storm. The cohesive approach"/>
 <result pre="clinical outcomes, which may be associated with acute respiratory distress" exact="syndrome" post="(ARDS) and cytokine storm. The cohesive approach amongst researchers"/>
 <result pre="cohesive approach amongst researchers across the globe has delivered high-end" exact="viral" post="diagnostics. However, home-based point-of-care diagnostics are still under development,"/>
 <result pre="review, we discuss the noteworthy advancements, focusing on the etiological" exact="viral" post="agent, comparative genomic analysis, population susceptibility, disease epidemiology and"/>
 <result pre="on the etiological viral agent, comparative genomic analysis, population susceptibility," exact="disease" post="epidemiology and diagnosis, animal reservoirs, laboratory animal models, disease"/>
 <result pre="susceptibility, disease epidemiology and diagnosis, animal reservoirs, laboratory animal models," exact="disease" post="transmission, therapeutics, vaccine challenges, and disease mitigation measures. coronavirus"/>
 <result pre="reservoirs, laboratory animal models, disease transmission, therapeutics, vaccine challenges, and" exact="disease" post="mitigation measures. coronavirus pandemic SARS-CoV-2 COVID-19 pathobiology diagnosis vaccines"/>
 <result pre="originated from a newly emerging coronavirus (CoV), designated as severe" exact="acute" post="respiratory syndrome coronavirus-2 (SARS-CoV-2) [1]. A live animal market"/>
 <result pre="from a newly emerging coronavirus (CoV), designated as severe acute" exact="respiratory" post="syndrome coronavirus-2 (SARS-CoV-2) [1]. A live animal market in"/>
 <result pre="a newly emerging coronavirus (CoV), designated as severe acute respiratory" exact="syndrome" post="coronavirus-2 (SARS-CoV-2) [1]. A live animal market in the"/>
 <result pre="of fever, cough, dyspnea, and fatigue, resembling symptoms common to" exact="viral pneumonia" post="[3]. The first case of respiratory illness of unknown"/>
 <result pre="fever, cough, dyspnea, and fatigue, resembling symptoms common to viral" exact="pneumonia" post="[3]. The first case of respiratory illness of unknown"/>
 <result pre="symptoms common to viral pneumonia [3]. The first case of" exact="respiratory" post="illness of unknown etiology occurred on 8 December 2019,"/>
 <result pre="shown in Figure 1. Consequently, a cluster of patients reported" exact="respiratory" post="illness to the local health care facilities, and on"/>
 <result pre="the Chinese National Health Commission (CNHC) suspected an outbreak of" exact="pneumonia" post="of unknown etiology in Wuhan. With the increasing number"/>
 <result pre="of cases in neighboring countries and other areas worldwide, the" exact="disease" post="spread to several countries worldwide and it was declared"/>
 <result pre="and China (84,507; 4645) [5]. Notably, all age groups show" exact="susceptibility to" post="SARS-CoV-2 infection, from newborns to the elderly [6]. The"/>
 <result pre="to the elderly [6]. The average age noted for SARS-CoV-2" exact="infection" post="susceptibility is 55.5 years, while that for the case"/>
 <result pre="risk. The most common reported comorbidities in COVID-19 cases include" exact="cardiovascular" post="diseases (10.5%), diabetes (7.3%), chronic respiratory infections (6.3%), hypertension"/>
 <result pre="common reported comorbidities in COVID-19 cases include cardiovascular diseases (10.5%)," exact="diabetes" post="(7.3%), chronic respiratory infections (6.3%), hypertension (6%), and malignancies"/>
 <result pre="comorbidities in COVID-19 cases include cardiovascular diseases (10.5%), diabetes (7.3%)," exact="chronic" post="respiratory infections (6.3%), hypertension (6%), and malignancies (5.6%) [8]."/>
 <result pre="in COVID-19 cases include cardiovascular diseases (10.5%), diabetes (7.3%), chronic" exact="respiratory" post="infections (6.3%), hypertension (6%), and malignancies (5.6%) [8]. As"/>
 <result pre="COVID-19 cases include cardiovascular diseases (10.5%), diabetes (7.3%), chronic respiratory" exact="infections" post="(6.3%), hypertension (6%), and malignancies (5.6%) [8]. As per"/>
 <result pre="include cardiovascular diseases (10.5%), diabetes (7.3%), chronic respiratory infections (6.3%)," exact="hypertension" post="(6%), and malignancies (5.6%) [8]. As per the WHO"/>
 <result pre="of infecting a new host have occurred previously in CoV" exact="infections" post="[14]. Earlier, reports suggested the emergence of SARS-CoV by"/>
 <result pre="civet CoVs prior to its spillover. Similarly, the Middle East" exact="respiratory" post="syndrome (MERS)-CoV also circulated and acquired mutations in camels"/>
 <result pre="CoVs prior to its spillover. Similarly, the Middle East respiratory" exact="syndrome" post="(MERS)-CoV also circulated and acquired mutations in camels for"/>
 <result pre="Similarly, the Middle East respiratory syndrome (MERS)-CoV also circulated and" exact="acquired" post="mutations in camels for approximately 30 years before the"/>
 <result pre="dissemination of the disease. 2. Previous Human CoV Epidemics Usually," exact="infections" post="caused by the Betacoronaviruses are mild to asymptomatic [19,20]."/>
 <result pre="To date, six strains of CoVs, causing mild to severe" exact="respiratory" post="illnesses in humans, have been identified [21]. Of these,"/>
 <result pre="humans. Contrarily, two highly pathogenic CoVs caused outbreaks of severe" exact="respiratory" post="illness due to zoonotic transmission in humans, namely the"/>
 <result pre="illness due to zoonotic transmission in humans, namely the severe" exact="acute" post="respiratory syndrome (SARS) and MERS. 2.1. SARS-CoV The first"/>
 <result pre="due to zoonotic transmission in humans, namely the severe acute" exact="respiratory" post="syndrome (SARS) and MERS. 2.1. SARS-CoV The first incidence"/>
 <result pre="to zoonotic transmission in humans, namely the severe acute respiratory" exact="syndrome" post="(SARS) and MERS. 2.1. SARS-CoV The first incidence of"/>
 <result pre="(SARS) and MERS. 2.1. SARS-CoV The first incidence of SARS-CoV" exact="infection" post="was reported on 16 November 2002, in the coastal"/>
 <result pre="province of southeast China bordering Hong Kong and Macau. This" exact="infection" post="spread across 31 countries at a moderate speed. The"/>
 <result pre="consisting of quarantine and the lockdown of air traffic, the" exact="disease" post="was finally contained by 5 July 2003 [22]. During"/>
 <result pre="infected 2496 humans with the deaths of 868 patients. The" exact="disease" post="was reported in Saudi Arabia, the UAE and the"/>
 <result pre="travel history to the Arabian Peninsular countries. The source of" exact="viral" post="origin was traced to bats, and camels were the"/>
 <result pre="viral origin was traced to bats, and camels were the" exact="intermediate" post="hosts for the virus, which followed animal-to-human (zoonotic disease)"/>
 <result pre="virus transmission [19,23]. 2.3. SARS-CoV-2 The first case of SARS-CoV-2" exact="infection" post="was reported in the first week of December 2019"/>
 <result pre="on Taxonomy of Viruses officially named it as the severe" exact="acute" post="respiratory syndrome coronavirus-2 (SARS-CoV-2), owing to its significant genetic"/>
 <result pre="Taxonomy of Viruses officially named it as the severe acute" exact="respiratory" post="syndrome coronavirus-2 (SARS-CoV-2), owing to its significant genetic relatedness"/>
 <result pre="of Viruses officially named it as the severe acute respiratory" exact="syndrome" post="coronavirus-2 (SARS-CoV-2), owing to its significant genetic relatedness to"/>
 <result pre="significant genetic relatedness to SARS-CoV. Subsequently, the WHO named the" exact="disease" post="caused by SARS-CoV-2 as coronavirus disease-2019 (COVID-19) on 11"/>
 <result pre="SARS-CoV, SARS-CoV-2, and bat-SARS CoV are considerably similar. The RNA" exact="secondary" post="structures in the 5â€²-UTR were more identical to those"/>
 <result pre="genomic level, the sequence homology of SARS-CoV-2 with MERS-CoV is" exact="lower" post="(50â€&quot;51.8%) than that with SARS-CoV (79%) [32]. Phylogenetically, SARS-CoV-2"/>
 <result pre="further experimental investigations. 4. CoV Receptors Host cell receptors and" exact="viral" post="surface glycoprotein/ligand binding serve as the most important determinants"/>
 <result pre="diversity in the RBDs of the S glycoprotein. However, CoV" exact="infections" post="in humans are primarily driven by interactions between the"/>
 <result pre="as ACE-2 (HCoV-NL63 and SARS). The key features of the" exact="external" post="subdomain of RBDs need to be investigated further to"/>
 <result pre="specific antiviral treatment, and the lack of specific vaccines, the" exact="primary" post="focus has been on minimizing contact with infected persons,"/>
 <result pre="the virus. Given this, we reviewed the available literature on" exact="viral" post="persistence on different contaminated surfaces that we commonly come"/>
 <result pre="for up to three hours, with a decline in the" exact="infectious" post="virus titer from 103.5 to 102.7 TCID50 per liter"/>
 <result pre="72 h when present on these contaminated surfaces. However, the" exact="infective" post="titer reduced significantly from 103.7 to 100.6 TCID50 on"/>
 <result pre="48 h on plastic and stainless steel surfaces [47]. A" exact="limited" post="number of low pathogenicity human CoVs, such as the"/>
 <result pre="nucleotide and amino acid levels, suggesting the stability of the" exact="viral" post="genome. To determine the similarity index between SARS-CoV-2 and"/>
 <result pre="separately, as shown in Figure 4. 7. Epidemiology of SARS-CoV-2" exact="Infection" post="The Wuhan seafood market in China was implicated as"/>
 <result pre="China was marked as the index country. Seven cases of" exact="pneumonia" post="of unknown etiology were reported in Wuhan from 8â€&quot;18"/>
 <result pre="cluster of such patients was identified on 21 December 2019." exact="Pneumonia" post="of unknown etiology is defined as an illness without"/>
 <result pre="or average white-cell count or low lymphocyte count, and no" exact="symptomatic" post="improvement after antimicrobial treatment for 3 to 5 days"/>
 <result pre="standard clinical guidelines [11,54]. The patients presented with a severe" exact="acute" post="respiratory infection and some developed acute respiratory distress syndrome"/>
 <result pre="clinical guidelines [11,54]. The patients presented with a severe acute" exact="respiratory" post="infection and some developed acute respiratory distress syndrome (ARDS)"/>
 <result pre="guidelines [11,54]. The patients presented with a severe acute respiratory" exact="infection" post="and some developed acute respiratory distress syndrome (ARDS) and"/>
 <result pre="presented with a severe acute respiratory infection and some developed" exact="acute" post="respiratory distress syndrome (ARDS) and associated complications [55]. 7.1."/>
 <result pre="with a severe acute respiratory infection and some developed acute" exact="respiratory" post="distress syndrome (ARDS) and associated complications [55]. 7.1. Transmission"/>
 <result pre="severe acute respiratory infection and some developed acute respiratory distress" exact="syndrome" post="(ARDS) and associated complications [55]. 7.1. Transmission Information about"/>
 <result pre="continuously evolving. Transmission primarily occurs via the person-to-person route through" exact="respiratory" post="droplets (&amp;gt;5â€&quot;10 Î¼m in diameter) and fomites. Droplet infection"/>
 <result pre="through respiratory droplets (&amp;gt;5â€&quot;10 Î¼m in diameter) and fomites. Droplet" exact="infection" post="is associated mainly with coughing, sneezing, and talking to"/>
 <result pre="to effectively contain the spread [11,56,57]. There is evidence of" exact="intestinal infection" post="from SARS-CoV-2, and subsequent excretion through feces [56,58]. In"/>
 <result pre="effectively contain the spread [11,56,57]. There is evidence of intestinal" exact="infection" post="from SARS-CoV-2, and subsequent excretion through feces [56,58]. In"/>
 <result pre="[56,58]. In China, out of ten pediatric COVID-19 patients without" exact="respiratory" post="symptoms, eight were positive for fecal SARS-CoV-2 shedding; however,"/>
 <result pre="date. Some reports suggest SARS-CoV-2 transmission through semen and the" exact="infection" post="of SARS-CoV-2 in newborns; however, there is no evidence"/>
 <result pre="however, there is no evidence for vertical transmission or intrauterine" exact="infection" post="in a COVID-19 patient during the late pregnancy stage"/>
 <result pre="transmission or intrauterine infection in a COVID-19 patient during the" exact="late pregnancy" post="stage [55]. 7.2. Incubation Period The incubation period for"/>
 <result pre="stage [55]. 7.2. Incubation Period The incubation period for SARS-CoV-2" exact="infection" post="ranged from 2 to 14 days in human-to-human transmission,"/>
 <result pre="(R0) The basic reproduction number plays a pivotal role in" exact="infectious disease" post="epidemiology and indicates the risk a pathogen carries with"/>
 <result pre="The basic reproduction number plays a pivotal role in infectious" exact="disease" post="epidemiology and indicates the risk a pathogen carries with"/>
 <result pre="transmissibility of a virus and represents the number of new" exact="infections" post="originating from an infected individual in a population. A"/>
 <result pre="to the use of different methods, insufficient data, and the" exact="short" post="onset time of the disease. 7.4. Population Susceptibility There"/>
 <result pre="age or those who have comorbidities (such as hypertension, diabetes," exact="cardiovascular" post="diseases, and respiratory system diseases) are highly susceptible to"/>
 <result pre="who have comorbidities (such as hypertension, diabetes, cardiovascular diseases, and" exact="respiratory" post="system diseases) are highly susceptible to the infection [25]."/>
 <result pre="diseases, and respiratory system diseases) are highly susceptible to the" exact="infection" post="[25]. Women are less susceptible to SARS-CoV-2 infection than"/>
 <result pre="to the infection [25]. Women are less susceptible to SARS-CoV-2" exact="infection" post="than men and this is possibly due to different"/>
 <result pre="virus load and inflammation. Recently, studies have shown that SARS-CoV-2" exact="infection" post="in children (though less severely affected), may develop the"/>
 <result pre="clear whether Kawasaki disease-like forms are a result of SARS-CoV-2" exact="infection" post="alone or just SARS-CoV-2 induced aggravations in Kawasaki disease"/>
 <result pre="of SARS-CoV-2 infection alone or just SARS-CoV-2 induced aggravations in" exact="Kawasaki disease" post="patients. 7.5. Global Scenario COVID-19 has affected almost every"/>
 <result pre="SARS-CoV-2 infection alone or just SARS-CoV-2 induced aggravations in Kawasaki" exact="disease" post="patients. 7.5. Global Scenario COVID-19 has affected almost every"/>
 <result pre="31 December 2019, an â€œurgent notice on the treatment of" exact="pneumonia" post="of unknown causeâ€� was issued to the Wuhan Municipal"/>
 <result pre="to wear masks. Till 3 January 2020, 44 case-patients with" exact="pneumonia" post="of unknown etiology were reported to the WHO from"/>
 <result pre="deaths. The WHO defined six regions to distribute the COVID-19" exact="disease" post="(Figure 5). Between 13â€&quot;20 January 2020, Thailand (the first"/>
 <result pre="on, the WHO named the virus as SARS-CoV-2, and the" exact="disease" post="was named COVID-19 (coronavirus disease 2019). Thus far, SARS-CoV-2"/>
 <result pre="virus as SARS-CoV-2, and the disease was named COVID-19 (coronavirus" exact="disease" post="2019). Thus far, SARS-CoV-2 has affected essentially all countries"/>
 <result pre="birds, camels, cattle, bats, and cats. CoVs primarily affect the" exact="upper" post="and lower respiratory tracts, and the enteric, hepatic, and"/>
 <result pre="cattle, bats, and cats. CoVs primarily affect the upper and" exact="lower" post="respiratory tracts, and the enteric, hepatic, and neurological systems,"/>
 <result pre="bats, and cats. CoVs primarily affect the upper and lower" exact="respiratory" post="tracts, and the enteric, hepatic, and neurological systems, with"/>
 <result pre="respiratory tracts, and the enteric, hepatic, and neurological systems, with" exact="infections" post="characterized by severe dyspnea and hypoxemia, renal dysfunction with"/>
 <result pre="infections characterized by severe dyspnea and hypoxemia, renal dysfunction with" exact="lower" post="urine output, tachycardia, altered mental status, and functional alterations"/>
 <result pre="symptoms, such as fever, fatigue, dry cough, myalgia, dyspnea, severe" exact="respiratory" post="distress syndrome, and acute cardiac injury [57,68,69]. There are"/>
 <result pre="fatigue, dry cough, myalgia, dyspnea, severe respiratory distress syndrome, and" exact="acute" post="cardiac injury [57,68,69]. There are three types of ARDS:"/>
 <result pre="Symptoms, such as headache, sputum production, hemoptysis, diarrhea, and pleuritic" exact="chest" post="pain were also observed in rare cases. The infection"/>
 <result pre="pleuritic chest pain were also observed in rare cases. The" exact="infection" post="more commonly affects people with cardiopulmonary or renal diseases,"/>
 <result pre="susceptibility among children. Pregnant women are at greater risk for" exact="viral" post="infections, as suggested by data from previous outbreaks; therefore,"/>
 <result pre="on the time of occurrence and intensity of symptoms, the" exact="infection" post="has been categorized into three stages; mild, severe, and"/>
 <result pre="and critical stage [71,72]. In the mild stage, mild pneumonia/no" exact="pneumonia" post="develops, although symptoms of upper respiratory tract viral infection,"/>
 <result pre="the mild stage, mild pneumonia/no pneumonia develops, although symptoms of" exact="upper" post="respiratory tract viral infection, marked by mild fever, dry"/>
 <result pre="mild stage, mild pneumonia/no pneumonia develops, although symptoms of upper" exact="respiratory" post="tract viral infection, marked by mild fever, dry cough,"/>
 <result pre="mild pneumonia/no pneumonia develops, although symptoms of upper respiratory tract" exact="viral infection," post="marked by mild fever, dry cough, sore throat, nasal"/>
 <result pre="fever, dry cough, sore throat, nasal congestion, malaise, headache, and" exact="muscle" post="pain, prevail [73]. In severely affected patients, the rate"/>
 <result pre="the rate of respiration is above 30/min due to dyspnea," exact="respiratory" post="symptoms, such as cough and shortness of breath, or"/>
 <result pre="critical stage is marked by symptoms, such as severe pneumonia," exact="septic shock," post="respiratory failure, cardiac arrest, and/or multiple organ failure, which"/>
 <result pre="is marked by symptoms, such as severe pneumonia, septic shock," exact="respiratory" post="failure, cardiac arrest, and/or multiple organ failure, which may"/>
 <result pre="by symptoms, such as severe pneumonia, septic shock, respiratory failure," exact="cardiac arrest," post="and/or multiple organ failure, which may eventually lead to"/>
 <result pre="mid, external, and sub-pleural areas of the lung [76]. A" exact="chest" post="radiograph, computer tomographic (CT) scan, and/or lung ultrasound indicate"/>
 <result pre="tomographic (CT) scan, and/or lung ultrasound indicate the presence of" exact="bilateral" post="opacities [55,77,78]. Thoracic CT scan imaging depicted bilateral ground-glass"/>
 <result pre="and/or lung ultrasound indicate the presence of bilateral opacities [55,77,78]." exact="Thoracic" post="CT scan imaging depicted bilateral ground-glass opacity and bilateral"/>
 <result pre="presence of bilateral opacities [55,77,78]. Thoracic CT scan imaging depicted" exact="bilateral" post="ground-glass opacity and bilateral multiple lobular and sub-segmental areas"/>
 <result pre="[55,77,78]. Thoracic CT scan imaging depicted bilateral ground-glass opacity and" exact="bilateral" post="multiple lobular and sub-segmental areas of consolidation [79,80,81]. The"/>
 <result pre="CT scan imaging depicted bilateral ground-glass opacity and bilateral multiple" exact="lobular" post="and sub-segmental areas of consolidation [79,80,81]. The pathological image"/>
 <result pre="consolidation [79,80,81]. The pathological image of a COVID-19 patient presented" exact="bilateral" post="diffuse alveolar damage with cellular fibromyxoid exudates. The cytopathic"/>
 <result pre="[79,80,81]. The pathological image of a COVID-19 patient presented bilateral" exact="diffuse" post="alveolar damage with cellular fibromyxoid exudates. The cytopathic effects"/>
 <result pre="a majority of lymphocytes and multinucleated syncytial cells, along with" exact="atypical" post="enlarged pneumocytes containing large nuclei and amphophilic granular cytoplasm,"/>
 <result pre="intra-alveolar spaces. In some infected patients, microvascular steatosis and mild" exact="lobular" post="and portal activity were recorded in hepatic tissues, while"/>
 <result pre="Immunopathobiology Existing literature documents that patients suffering from severe SARS-CoV-2" exact="infection" post="might suffer from the cytokine storm syndrome that could"/>
 <result pre="from severe SARS-CoV-2 infection might suffer from the cytokine storm" exact="syndrome" post="that could eventually lead to death [82,83]. In a"/>
 <result pre="syndrome that could eventually lead to death [82,83]. In a" exact="viral infection," post="cell-mediated immunity is triggered to overcome the infection; however,"/>
 <result pre="events can have drastic effects in certain patients [84]. Evidently," exact="respiratory" post="failure due to the ARDS is the leading cause"/>
 <result pre="is the leading cause of mortality, and, apart from this," exact="secondary" post="hemophagocytic lymphohistiocytosis is also induced in a limited number"/>
 <result pre="the leading cause of mortality, and, apart from this, secondary" exact="hemophagocytic lymphohistiocytosis" post="is also induced in a limited number of adult"/>
 <result pre="from this, secondary hemophagocytic lymphohistiocytosis is also induced in a" exact="limited" post="number of adult COVID-19 patients. Usually, it is one"/>
 <result pre="hemophagocytic lymphohistiocytosis is also induced in a limited number of" exact="adult" post="COVID-19 patients. Usually, it is one of the less-recognized"/>
 <result pre="interleukin (IL)-2, IL-7, macrophage inflammatory protein 1-Î±, granulocyte colony-stimulating factor," exact="tumor" post="necrosis factor-Î±, interferon-Î³ inducible protein 10, and monocyte chemoattractant"/>
 <result pre="colony-stimulating factor, tumor necrosis factor-Î±, interferon-Î³ inducible protein 10, and" exact="monocyte" post="chemoattractant protein 1. Mortality in COVID-19 could be attributed"/>
 <result pre="attributed to such hyperinflammatory reactions [82,85]. Clinical laboratory findings suggested" exact="leucopenia" post="(white blood cell count less than 2.91 Ã— 109/l)"/>
 <result pre="(white blood cell count less than 2.91 Ã— 109/l) and" exact="lymphopenia" post="(lymphocyte count less than 1.0 Ã— 109/l), high erythrocyte"/>
 <result pre="in hypersensitive troponin I (hs-cTnI) as a sign of virus-induced" exact="heart" post="tissue damage, and a marked increase in the concentration"/>
 <result pre="the concentration of serum C-reactive protein and D-dimer, hyperbilirubinemia, and" exact="acidosis" post="[3,24]. Studies on the pathogenesis of COVID-19 have not"/>
 <result pre="and ACE-2, the antigen-presenting cells are likely to process the" exact="viral" post="proteins through the major histocompatibility complex (MHC or human"/>
 <result pre="at a similar point or slightly earlier than in SARS-CoV" exact="infection" post="[86,87]. A recently released antibody profile against SARS-CoV-2 has"/>
 <result pre="the levels of CD4 and CD8 T cells in the" exact="peripheral" post="blood of SARS-CoV-2-infected patients [89]. Studies on COVID-19-recovered patients"/>
 <result pre="against SARS-CoV-2. Increasing evidence suggests that fatalities resulting from SARS-CoV-2" exact="infection" post="could be primarily attributed to the ARDS [90,91], which"/>
 <result pre="feature common to SARS-CoV-1, MERS-CoV, and the more recent SARS-CoV-2" exact="infections" post="[89,93]. ARDS occurs primarily in response to the cytokine"/>
 <result pre="occurs primarily in response to the cytokine storm, the fatal" exact="uncontrolled" post="systemic inflammatory response, resulting from the release of an"/>
 <result pre="primarily in response to the cytokine storm, the fatal uncontrolled" exact="systemic" post="inflammatory response, resulting from the release of an excess"/>
 <result pre="MCP1, MIP1Î±, and TNF) from immune effector cells during SARS-CoV-2" exact="infection" post="[91,93,94,95,96,97,98]. In this context, the increased levels of IL-6"/>
 <result pre="indicator of poor prognosis in the severe stage of the" exact="disease" post="[98]. The cytokine storm triggers a severe attack by"/>
 <result pre="of SARS-CoV-2 infections, similar to that in SARS-CoV and MERS-CoV" exact="infections" post="[89,94]. A recent study also supported the proposition that"/>
 <result pre="[94,95,97]. 10. Animal Reservoirs The identification of animal reservoirs or" exact="intermediate" post="host(s) and the evolution of SARS-CoV-2 is critical to"/>
 <result pre="based on synonymous codon usage bias suggested snakes as an" exact="intermediate" post="host; however, this virus has not been detected in"/>
 <result pre="[100]. Later on, pangolins were found to be a potential" exact="intermediate" post="host. The recent detection and whole-genome sequence analysis of"/>
 <result pre="identity of 85.5 to 92.4% with pangolin SARS-CoV-2, which is" exact="lower" post="compared to that of bat CoV RaTG13 (96.2%). However,"/>
 <result pre="This finding suggests that pangolins may act as a potential" exact="intermediate" post="host. However, studies suggesting bats as a reservoir host"/>
 <result pre="suggesting bats as a reservoir host and pangolins as an" exact="intermediate" post="host for SARS-CoV-2 need to be investigated further. Susceptibility"/>
 <result pre="it replicated poorly in pigs, dogs, chickens, and ducks [102]." exact="Viral" post="transmission via respiratory droplets was also noted in cats"/>
 <result pre="in pigs, dogs, chickens, and ducks [102]. Viral transmission via" exact="respiratory" post="droplets was also noted in cats in this study."/>
 <result pre="positive for SARS-CoV-2 [103]. The gene sequence analysis of the" exact="viral" post="isolate from a dog indicates that the dog might"/>
 <result pre="isolate from a dog indicates that the dog might have" exact="acquired" post="the infection from infected individuals. These findings suggest low"/>
 <result pre="a dog indicates that the dog might have acquired the" exact="infection" post="from infected individuals. These findings suggest low chances of"/>
 <result pre="ongoing search for a suitable animal model to study SARS-CoV-2" exact="infection" post="[104]. After the SARS outbreak, numerous inbred mouse strains"/>
 <result pre="inbred mouse strains were evaluated as models for the SARS-CoV" exact="disease" post="with varying levels of results [105,106]. The genetically engineered"/>
 <result pre="and monkeys [107]. Recently, ferrets have been identified as an" exact="infection" post="and transmission animal model for studying SARS-CoV-2. This finding"/>
 <result pre="12.1. Sample Collection For patients under investigation, the collection of" exact="upper" post="respiratory samples (nasopharyngeal and oropharyngeal swabs) and lower respiratory"/>
 <result pre="Sample Collection For patients under investigation, the collection of upper" exact="respiratory" post="samples (nasopharyngeal and oropharyngeal swabs) and lower respiratory samples"/>
 <result pre="collection of upper respiratory samples (nasopharyngeal and oropharyngeal swabs) and" exact="lower" post="respiratory samples (sputum, if possible) is recommended irrespective of"/>
 <result pre="of upper respiratory samples (nasopharyngeal and oropharyngeal swabs) and lower" exact="respiratory" post="samples (sputum, if possible) is recommended irrespective of the"/>
 <result pre="be tested to exclude other unidentified modes of transmission [3]." exact="Respiratory" post="samples should be collected in viral transport medium with"/>
 <result pre="modes of transmission [3]. Respiratory samples should be collected in" exact="viral" post="transport medium with antibiotics and antifungals and transported in"/>
 <result pre="found to test positive for SARS-CoV-2 in 91.7% of the" exact="symptomatic" post="cases, and a declining trend in viral load has"/>
 <result pre="91.7% of the symptomatic cases, and a declining trend in" exact="viral" post="load has also been reported. This finding is of"/>
 <result pre="[109]. Zhang et al. used anal swabs in addition to" exact="respiratory" post="samples and found a higher number of positive cases"/>
 <result pre="a higher number of positive cases using anal swabs than" exact="respiratory" post="swabs, especially in the later stages of infection [60]."/>
 <result pre="swabs than respiratory swabs, especially in the later stages of" exact="infection" post="[60]. 12.2. Diagnostic Technologies Sensitive and specific diagnostic methods"/>
 <result pre="being tested and applied for preliminary screening of possible early" exact="infections" post="of SARS-CoV-2 among individuals. Based on the AI-based learning"/>
 <result pre="considered sensitive, owing to concerns of national security [117]. The" exact="chest" post="CT-based diagnosis, usually in COVID-19, has certain limitations in"/>
 <result pre="COVID-19 was developed and employed to distinguish the common community-acquired" exact="pneumonia" post="from COVID-19 [118]. With a lack of point-of-care diagnostics,"/>
 <result pre="made globally to develop safe and effective vaccines against SARS-CoV-2" exact="infection" post="[120]. Approximately 200 vaccine candidates have already been developed"/>
 <result pre="using at least seven different approaches, which include mRNA vaccine," exact="viral" post="vector vaccine, DNA vaccine, recombinant protein-based vaccine, peptide-based, virus-like"/>
 <result pre="been jointly developed by the National Institute of Allergy and" exact="Infectious" post="Diseases (NIAID), USA and Moderna, Cambridge, Massachusetts, as shown"/>
 <result pre="jointly developed by the National Institute of Allergy and Infectious" exact="Diseases" post="(NIAID), USA and Moderna, Cambridge, Massachusetts, as shown in"/>
 <result pre="of such a vaccine is its ability to mimic natural" exact="infection" post="to trigger a more potent immune response and rapid"/>
 <result pre="in Table 5. A concept of protection through changing the" exact="viral" post="genetic code was given by researchers from China in"/>
 <result pre="immediate development of effective and safe therapeutic strategies. In the" exact="absence of" post="licensed vaccines and approved antiviral drugs, the most promising"/>
 <result pre="China in February 2020, is commonly used to treat influenza" exact="infection" post="in China and Japan and has shown promising results"/>
 <result pre="has shown promising results in shortening the course of SARS-CoV-2" exact="infection" post="[12,124,125]. This drug acts by inhibiting the RNA-dependent RNA"/>
 <result pre="drug that was initially developed for the treatment of Ebola" exact="virus infection." post="Remdisivir is reported to prevent viral replication by the"/>
 <result pre="treatment of Ebola virus infection. Remdisivir is reported to prevent" exact="viral" post="replication by the premature termination of RNA transcription. Currently,"/>
 <result pre="combination of lopinavir and ritonavir was developed to treat HIV-1" exact="infections" post="in adults. However, the combination of lopinavir and ritonavir"/>
 <result pre="results in an open-label non-randomized clinical trial in reducing the" exact="viral" post="load in COVID-19 patients [129]. However, its associated side-effects"/>
 <result pre="side-effects could be more severe in COVID-19 patients with pre-existing" exact="chronic" post="medical conditions. Apart from these drugs, convalescent plasma therapy"/>
 <result pre="reported its significant effectiveness in controlling fever and improving the" exact="respiratory" post="function in individuals with severe COVID-19 [98]. Apart from"/>
 <result pre="safe outcome and need an assessment of immune responses and" exact="disease" post="enhancement. Lately, other concerns posing a challenge are higher"/>
 <result pre="virus into the host cells and is well described in" exact="viral" post="infections. â€œWill the changing virus remain susceptible to the"/>
 <result pre="questions yet to be resolved. 14. Mitigation Strategies In the" exact="absence of" post="approved antiviral agents and vaccines, the most effective strategies"/>
 <result pre="patient (within three feet) or are performing aerosol-generating procedures on" exact="symptomatic" post="patients. These masks are not recommended for use by"/>
 <result pre="of N95 masks after ethylene oxide sterilization may be considered." exact="General" post="public awareness should be increased by the display of"/>
 <result pre="the workplace to prevent the spread to family members. The" exact="consumption" post="of undercooked and raw meat should strictly be avoided."/>
 <result pre="is the third event of the spillover of a zoonotic" exact="respiratory" post="virus to humans in this decade of the 21st"/>
 <result pre="the environment [143,144]. WHO initiatives, such as the Battle against" exact="Respiratory" post="Viruses (BRaVe), that support innovative multidisciplinary research in the"/>
 <result pre="innovative multidisciplinary research in the field of emerging and re-emerging" exact="respiratory" post="viruses are encouraging [145]. Consortiums and open-access platforms, such"/>
 <result pre="encouraging [145]. Consortiums and open-access platforms, such as ProMed, International" exact="Severe" post="Acute Respiratory and Emerging Infection Consortium, and BioDiaspora, act"/>
 <result pre="[145]. Consortiums and open-access platforms, such as ProMed, International Severe" exact="Acute" post="Respiratory and Emerging Infection Consortium, and BioDiaspora, act as"/>
 <result pre="Consortiums and open-access platforms, such as ProMed, International Severe Acute" exact="Respiratory" post="and Emerging Infection Consortium, and BioDiaspora, act as benefactors"/>
 <result pre="platforms, such as ProMed, International Severe Acute Respiratory and Emerging" exact="Infection" post="Consortium, and BioDiaspora, act as benefactors by partaking in,"/>
 <result pre="infected individuals while others remain asymptomatic, and the reappearance of" exact="infection" post="in specific cured individuals, among others. With the availability"/>
 <result pre="specific cured individuals, among others. With the availability of more" exact="complete" post="genome sequences from different parts of the world, it"/>
 <result pre="published version of the manuscript Funding This research received no" exact="external" post="funding. Conflicts of Interest The authors declare no conflict"/>
 <result pre="declare no conflict of interest. References References 1.GorbalenyaA.E.BakerS.C.BaricR.S.de GrootR.J.DrostenC.GulyaevaA.A.HaagmansB.L.LauberC.LeontovichA.M.NeumanB.W.et al.Severe" exact="acute" post="respiratory syndrome-related coronavirus: The species and its virusesâ€&quot;A statement"/>
 <result pre="no conflict of interest. References References 1.GorbalenyaA.E.BakerS.C.BaricR.S.de GrootR.J.DrostenC.GulyaevaA.A.HaagmansB.L.LauberC.LeontovichA.M.NeumanB.W.et al.Severe acute" exact="respiratory" post="syndrome-related coronavirus: The species and its virusesâ€&quot;A statement of"/>
 <result pre="Declares COVID-19 a PandemicActa Biomed.20209115716032191675 5.collab: World Health Organization (WHO)Coronavirus" exact="Disease" post="2019 (COVID-19) Situation Reportâ€&quot;93Available online: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200422-sitrep-93-covid-19.pdf?sfvrsn=35cf80d7_4(accessed on 23 April"/>
 <result pre="Situation Reportâ€&quot;93Available online: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200422-sitrep-93-covid-19.pdf?sfvrsn=35cf80d7_4(accessed on 23 April 2020) 6.WeiM.YuanJ.LiuY.FuT.YuX.ZhangZ.J.Novel coronavirus" exact="infection" post="in hospitalized infants under 1 year of age in"/>
 <result pre="and clinical characteristics of 99 cases of 2019 novel coronavirus" exact="pneumonia" post="in Wuhan, China: A descriptive studyLancet202039550751310.1016/S0140-6736(20)30211-732007143 8.WangD.HuB.HuC.ZhuF.LiuX.ZhangJ.WangB.XiangH.ChengZ.XiongY.et al.Clinical characteristics"/>
 <result pre="al.Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected" exact="pneumonia" post="in Wuhan, ChinaJ. Am. Med. Assoc.20203231061106910.1001/jama.2020.1585 9.CaiH.Sex difference and"/>
 <result pre="Respir. Med.20208e2010.1016/S2213-2600(20)30117-X32171067 10.YuW.-B.TangG.-D.ZhangL.CorlettR.Decoding the evolution and transmissions of the novel" exact="pneumonia" post="coronavirus (SARS-CoV-2) using the whole genomic dataZool Res.20204124725710.24272/j.issn.2095-8137.2020.02232351056 11.LiQ.GuanX.WuP.WangX.ZhouL.TongY.RenR.LeungK.S.M.LauE.H.Y.WongJ.Y.et"/>
 <result pre="J. Med.20203821199120710.1056/NEJMoa200131631995857 12.GuoY.R.CaoQ.D.HongZ.S.TanY.Y.ChenS.D.JinH.J.TanK.S.WangD.Y.YanY.The origin, transmission and clinical therapies on coronavirus" exact="disease" post="2019 (COVID-19) outbreakâ€&quot;An update on the statusMil. Med. Res.202071110.1186/s40779-020-00240-032169119"/>
 <result pre="Med. Res.202071110.1186/s40779-020-00240-032169119 13.HodgsonJ.The pandemic pipelineNat. Biotechnol.20203852353210.1038/d41587-020-00005-z32203293 14.RotheC.SchunkM.SothmannP.BretzelG.FroeschlG.WallrauchC.ZimmerT.ThielV.JankeC.GuggemosW.et al.Transmission of 2019-nCoV" exact="infection" post="from an asymptomatic contact in GermanyN. Engl. J. Med.202038297097110.1056/NEJMc200146832003551"/>
 <result pre="Infect. Dis.2014202093209510.3201/eid2012.14102625425139 17.EllwangerJ.H.ChiesJ.A.B.Wind: A neglected factor in the spread of" exact="infectious" post="diseasesLancet Planet. Health20182e47510.1016/S2542-5196(18)30238-930396437 18.LamT.T.-Y.ShumM.H.-H.ZhuH.-C.TongY.-G.NiX.-B.LiaoY.-S.WeiW.CheungW.Y.-M.LiW.-J.LiL.-F.et al.Identifying SARS-CoV-2 related coronaviruses in"/>
 <result pre="shedding and antibody response in 37 patients with Middle East" exact="respiratory" post="syndrome coronavirus infectionClin. Infect. Dis.20166247748310.1093/cid/civ95126565003 21.SuS.WongG.ShiW.LiuJ.LaiA.C.ZhouJ.LiuW.BiY.GaoG.F.Epidemiology, genetic recombination, and"/>
 <result pre="and antibody response in 37 patients with Middle East respiratory" exact="syndrome" post="coronavirus infectionClin. Infect. Dis.20166247748310.1093/cid/civ95126565003 21.SuS.WongG.ShiW.LiuJ.LaiA.C.ZhouJ.LiuW.BiY.GaoG.F.Epidemiology, genetic recombination, and pathogenesis"/>
 <result pre="Dis.20166247748310.1093/cid/civ95126565003 21.SuS.WongG.ShiW.LiuJ.LaiA.C.ZhouJ.LiuW.BiY.GaoG.F.Epidemiology, genetic recombination, and pathogenesis of coronavirusesTrends Microbiol.20162449050210.1016/j.tim.2016.03.00327012512 22.VijayanandP.WilkinsE.WoodheadM.Severe" exact="acute" post="respiratory syndrome (SARS): A reviewClin. Med. (Lond.)2004415216010.7861/clinmedicine.4-2-15215139736 23.RamadanN.ShaibH.Middle East"/>
 <result pre="21.SuS.WongG.ShiW.LiuJ.LaiA.C.ZhouJ.LiuW.BiY.GaoG.F.Epidemiology, genetic recombination, and pathogenesis of coronavirusesTrends Microbiol.20162449050210.1016/j.tim.2016.03.00327012512 22.VijayanandP.WilkinsE.WoodheadM.Severe acute" exact="respiratory" post="syndrome (SARS): A reviewClin. Med. (Lond.)2004415216010.7861/clinmedicine.4-2-15215139736 23.RamadanN.ShaibH.Middle East respiratory"/>
 <result pre="genetic recombination, and pathogenesis of coronavirusesTrends Microbiol.20162449050210.1016/j.tim.2016.03.00327012512 22.VijayanandP.WilkinsE.WoodheadM.Severe acute respiratory" exact="syndrome" post="(SARS): A reviewClin. Med. (Lond.)2004415216010.7861/clinmedicine.4-2-15215139736 23.RamadanN.ShaibH.Middle East respiratory syndrome"/>
 <result pre="acute respiratory syndrome (SARS): A reviewClin. Med. (Lond.)2004415216010.7861/clinmedicine.4-2-15215139736 23.RamadanN.ShaibH.Middle East" exact="respiratory" post="syndrome coronavirus (MERS-CoV): A reviewGerms20199354210.18683/germs.2019.115531119115 24.ZhouP.YangX.L.WangX.G.HuB.ZhangL.ZhangW.SiH.R.ZhuY.LiB.HuangC.L.et al.A pneumonia outbreak"/>
 <result pre="respiratory syndrome (SARS): A reviewClin. Med. (Lond.)2004415216010.7861/clinmedicine.4-2-15215139736 23.RamadanN.ShaibH.Middle East respiratory" exact="syndrome" post="coronavirus (MERS-CoV): A reviewGerms20199354210.18683/germs.2019.115531119115 24.ZhouP.YangX.L.WangX.G.HuB.ZhangL.ZhangW.SiH.R.ZhuY.LiB.HuangC.L.et al.A pneumonia outbreak associated"/>
 <result pre="23.RamadanN.ShaibH.Middle East respiratory syndrome coronavirus (MERS-CoV): A reviewGerms20199354210.18683/germs.2019.115531119115 24.ZhouP.YangX.L.WangX.G.HuB.ZhangL.ZhangW.SiH.R.ZhuY.LiB.HuangC.L.et al.A" exact="pneumonia" post="outbreak associated with a new coronavirus of probable bat"/>
 <result pre="the 2019 novel human-pathogenic coronavirus isolated from a patient with" exact="atypical pneumonia" post="after visiting WuhanEmerg. Microbes Infect.2020922123610.1080/22221751.2020.171990231987001 27.de GrootR.J.BakerS.BaricR.EnjuanesL.GorbalenyaA.HolmesK.PerlmanS.PoonL.RottierP.TalbotP.Family coronaviridaeVirus Taxonomy:"/>
 <result pre="2019 novel human-pathogenic coronavirus isolated from a patient with atypical" exact="pneumonia" post="after visiting WuhanEmerg. Microbes Infect.2020922123610.1080/22221751.2020.171990231987001 27.de GrootR.J.BakerS.BaricR.EnjuanesL.GorbalenyaA.HolmesK.PerlmanS.PoonL.RottierP.TalbotP.Family coronaviridaeVirus Taxonomy:"/>
 <result pre="PressCambridge, MA, USA2012806828 28.ZhuN.ZhangD.WangW.LiX.YangB.SongJ.ZhaoX.HuangB.ShiW.LuR.et al.A novel coronavirus from patients with" exact="pneumonia" post="in China, 2019N. Engl. J. Med.202038272773310.1056/NEJMoa200101731978945 29.WuA.PengY.HuangB.DingX.WangX.NiuP.MengJ.ZhuZ.ZhangZ.WangJ.et al.Genome composition"/>
 <result pre="vaccineBiochem. Biophys. Res. Commun.200432477378110.1016/j.bbrc.2004.09.10615474494 36.Le CoupanecA.DesforgesM.Meessen-PinardM.DubeM.DayR.SeidahN.G.TalbotP.J.Cleavage of a neuroinvasive human" exact="respiratory" post="virus spike glycoprotein by proprotein convertases modulates neurovirulence and"/>
 <result pre="fusionProc. Natl. Acad. Sci. USA2017114111571116210.1073/pnas.170872711429073020 39.BassiD.E.ZhangJ.RennerC.Klein-SzantoA.J.Targeting proprotein convertases in furin-rich" exact="lung cancer" post="cells results in decreased in vitro and in vivo"/>
 <result pre="Natl. Acad. Sci. USA2017114111571116210.1073/pnas.170872711429073020 39.BassiD.E.ZhangJ.RennerC.Klein-SzantoA.J.Targeting proprotein convertases in furin-rich lung" exact="cancer" post="cells results in decreased in vitro and in vivo"/>
 <result pre="An integrated modeling systemJ. Struct. Biol.201217926927810.1016/j.jsb.2011.09.00621963794 41.LiF.Receptor recognition and cross-species" exact="infections" post="of SARS coronavirusAntivir. Res.201310024625410.1016/j.antiviral.2013.08.01423994189 42.LiF.Receptor recognition mechanisms of coronaviruses:"/>
 <result pre="with SARS-CoV-1N. Engl. J. Med.20203821564156710.1056/NEJMc200497332182409 47.Van DoremalenN.BushmakerT.MunsterV.Stability of Middle East" exact="respiratory" post="syndrome coronavirus (MERS-CoV) under different environmental conditionsEurosurveillance2013182059010.2807/1560-7917.ES2013.18.38.2059024084338 48.SizunJ.YuM.TalbotP.Survival of"/>
 <result pre="SARS-CoV-1N. Engl. J. Med.20203821564156710.1056/NEJMc200497332182409 47.Van DoremalenN.BushmakerT.MunsterV.Stability of Middle East respiratory" exact="syndrome" post="coronavirus (MERS-CoV) under different environmental conditionsEurosurveillance2013182059010.2807/1560-7917.ES2013.18.38.2059024084338 48.SizunJ.YuM.TalbotP.Survival of human"/>
 <result pre="possible source ofhospital-acquired infectionsJ. Hosp. Infect.200046556010.1053/jhin.2000.079511023724 49.WarnesS.L.LittleZ.R.KeevilC.W.Human coronavirus 229E remains" exact="infectious" post="on common touch surface materialsmBio20156e01697e0171510.1128/mBio.01697-1526556276 50.RabenauH.CinatlJ.MorgensternB.BauerG.PreiserW.DoerrH.Stability and inactivation of"/>
 <result pre="WHO-recommended hand rub formulations and alcoholsbioRxiv202010.1101/2020.03.10.986711 52.KratzelA.TodtD.Vâ€™KovskiP.SteinerS.GultomM.ThaoT.T.N.EbertN.HolwerdaM.SteinmannJ.NiemeyerD.et al.Inactivation of severe" exact="acute" post="respiratory syndrome coronavirus 2 by WHO-Recommended hand rub formulations"/>
 <result pre="hand rub formulations and alcoholsbioRxiv202010.1101/2020.03.10.986711 52.KratzelA.TodtD.Vâ€™KovskiP.SteinerS.GultomM.ThaoT.T.N.EbertN.HolwerdaM.SteinmannJ.NiemeyerD.et al.Inactivation of severe acute" exact="respiratory" post="syndrome coronavirus 2 by WHO-Recommended hand rub formulations and"/>
 <result pre="rub formulations and alcoholsbioRxiv202010.1101/2020.03.10.986711 52.KratzelA.TodtD.Vâ€™KovskiP.SteinerS.GultomM.ThaoT.T.N.EbertN.HolwerdaM.SteinmannJ.NiemeyerD.et al.Inactivation of severe acute respiratory" exact="syndrome" post="coronavirus 2 by WHO-Recommended hand rub formulations and alcoholsEmerg."/>
 <result pre="updates and new developmentsNucleic Acids Res.201947W256W25910.1093/nar/gkz23930931475 54.XiangN.HaversF.ChenT.SongY.TuW.LiL.CaoY.LiuB.ZhouL.MengL.et al.Use of national" exact="pneumonia" post="surveillance to describe influenza A(H7N9) virus epidemiology, China, 2004â€&quot;2013Emerg."/>
 <result pre="55.ChenH.GuoJ.WangC.LuoF.YuX.ZhangW.LiJ.ZhaoD.XuD.GongQ.et al.Clinical characteristics and intrauterine vertical transmission potential of COVID-19" exact="infection" post="in nine pregnant women: A retrospective review of medical"/>
 <result pre="58.HindsonJ.COVID-19: Faecalâ€&quot;oral transmission?Nat. Rev. Gastroenterol. Hepatol.20201725910.1038/s41575-020-0295-732214231 59.XuY.LiX.ZhuB.LiangH.FangC.GongY.GuoQ.SunX.ZhaoD.ShenJ.Characteristics of pediatric SARS-CoV-2" exact="infection" post="and potential evidence for persistent fecal viral sheddingNat. Med.20202650250510.1038/s41591-020-0817-432284613"/>
 <result pre="of pediatric SARS-CoV-2 infection and potential evidence for persistent fecal" exact="viral" post="sheddingNat. Med.20202650250510.1038/s41591-020-0817-432284613 60.ZhangW.DuR.H.LiB.ZhengX.S.YangX.L.HuB.WangY.Y.XiaoG.F.YanB.ShiZ.L.et al.Molecular and serological investigation of 2019-nCoV"/>
 <result pre="multiple shedding routesEmerg. Microbes Infect.2020938638910.1080/22221751.2020.172907132065057 61.collab: World Health Organization (WHO)Coronavirus" exact="Disease" post="2019 (COVID-19)Situation Reportâ€&quot;30Available online: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200219-sitrep-30-covid-19.pdf?sfvrsn=3346b04f_2(accessed on 8 April 2020)"/>
 <result pre="63.ContiP.YounesA.Coronavirus COV-19/SARS-CoV-2 Affects Women Less Than Men: Clinical Response to" exact="Viral" post="InfectionJ. Biol. Regul. Homeost. Agents.2020347110.23812/Editorial-Conti-332064838 64.RonconiG.TetÃ©G.KritasS.K.GallengaC.E.CaraffaA.RossR.ContiP.SARS-CoV-2, Which Induces COVID-19,"/>
 <result pre="Biol. Regul. Homeost. Agents.2020347110.23812/Editorial-Conti-332064838 64.RonconiG.TetÃ©G.KritasS.K.GallengaC.E.CaraffaA.RossR.ContiP.SARS-CoV-2, Which Induces COVID-19, Causes Kawasaki-Like" exact="Disease" post="in Children: Role of Pro-Inflammatory and Anti-Inflammatory CytokinesJ. Biol."/>
 <result pre="CytokinesJ. Biol. Regul. Homeost. Agents.20203410.23812/EDITORIAL-RONCONI-E-59 65.collab: World Health Organization (WHO)Coronavirus" exact="Disease" post="(COVID-19) Technical GuidanceAvailable online: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/laboratory-guidance(accessed on 28 March 2020)"/>
 <result pre="https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/laboratory-guidance(accessed on 28 March 2020) 66.collab: World Health Organization (WHO)Coronavirus" exact="Disease" post="2019 (COVID-19) Situation Reportâ€&quot;2Available online: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200122-sitrep-2-2019-ncov.pdf?sfvrsn=4d5bcbca_2(accessed on 15 March"/>
 <result pre="https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200122-sitrep-2-2019-ncov.pdf?sfvrsn=4d5bcbca_2(accessed on 15 March 2020) 67.collab: World Health Organization (WHO)Coronavirus" exact="Disease" post="2019 (COVID-19) Situation Reportâ€&quot;81Available online: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200410-sitrep-81-covid-19.pdf?sfvrsn=ca96eb84_2(accessed on 22 March"/>
 <result pre="on 22 March 2020) 68.RothanH.A.ByrareddyS.N.The epidemiology and pathogenesis of coronavirus" exact="disease" post="(COVID-19) outbreakJ. Autoimmun.202010.1016/j.jaut.2020.10243332113704 69.HuZ.SongC.XuC.JinG.ChenY.XuX.MaH.ChenW.LinY.ZhengY.Clinical characteristics of 24 asymptomatic infections"/>
 <result pre="coronavirus disease (COVID-19) outbreakJ. Autoimmun.202010.1016/j.jaut.2020.10243332113704 69.HuZ.SongC.XuC.JinG.ChenY.XuX.MaH.ChenW.LinY.ZhengY.Clinical characteristics of 24 asymptomatic" exact="infections" post="with COVID-19 screened among close contacts in Nanjing, ChinaSci."/>
 <result pre="contacts in Nanjing, ChinaSci. China Life Sci.20206370671110.1007/s11427-020-1661-432146694 70.collab: Centers for" exact="Disease" post="Control and Prevention (CDC)Coronavirus Disease (COVID-19) Pregnancy and BreastfeedingAvailable"/>
 <result pre="Life Sci.20206370671110.1007/s11427-020-1661-432146694 70.collab: Centers for Disease Control and Prevention (CDC)Coronavirus" exact="Disease" post="(COVID-19) Pregnancy and BreastfeedingAvailable online: https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/pregnancy-breastfeeding.html(accessed on 7 June"/>
 <result pre="70.collab: Centers for Disease Control and Prevention (CDC)Coronavirus Disease (COVID-19)" exact="Pregnancy" post="and BreastfeedingAvailable online: https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/pregnancy-breastfeeding.html(accessed on 7 June 2020) 71.SinghalT.A"/>
 <result pre="2020) 71.SinghalT.A review of coronavirus disease-2019 (COVID-19)Indian J. Pediatr.20208728128610.1007/s12098-020-03263-632166607 72.HeF.DengY.LiW.Coronavirus" exact="disease" post="2019: What we know?J. Med. Virol.20209271972510.1002/jmv.2576632170865 73.XuZ.ShiL.WangY.ZhangJ.HuangL.ZhangC.LiuS.ZhaoP.LiuH.ZhuL.et al.Pathological findings"/>
 <result pre="know?J. Med. Virol.20209271972510.1002/jmv.2576632170865 73.XuZ.ShiL.WangY.ZhangJ.HuangL.ZhangC.LiuS.ZhaoP.LiuH.ZhuL.et al.Pathological findings of COVID-19 associated with" exact="acute" post="respiratory distress syndromeLancet Respir. Med.2020842042210.1016/S2213-2600(20)30076-X32085846 74.ChanK.H.PeirisJ.S.LamS.Y.PoonL.L.YuenK.Y.SetoW.H.The Effects of temperature"/>
 <result pre="Med. Virol.20209271972510.1002/jmv.2576632170865 73.XuZ.ShiL.WangY.ZhangJ.HuangL.ZhangC.LiuS.ZhaoP.LiuH.ZhuL.et al.Pathological findings of COVID-19 associated with acute" exact="respiratory" post="distress syndromeLancet Respir. Med.2020842042210.1016/S2213-2600(20)30076-X32085846 74.ChanK.H.PeirisJ.S.LamS.Y.PoonL.L.YuenK.Y.SetoW.H.The Effects of temperature and"/>
 <result pre="on the viability of the SARS coronavirusAdv. Virol.2011201173469010.1155/2011/73469022312351 75.ChanJ.F.YuanS.KokK.H.ToK.K.ChuH.YangJ.XingF.LiuJ.YipC.C.PoonR.W.et al.A" exact="familial" post="cluster of pneumonia associated with the 2019 novel coronavirus"/>
 <result pre="of the SARS coronavirusAdv. Virol.2011201173469010.1155/2011/73469022312351 75.ChanJ.F.YuanS.KokK.H.ToK.K.ChuH.YangJ.XingF.LiuJ.YipC.C.PoonR.W.et al.A familial cluster of" exact="pneumonia" post="associated with the 2019 novel coronavirus indicating person-to-person transmission:"/>
 <result pre="Pathol.202049411417 77.XuY.H.DongJ.H.AnW.M.LvX.Y.YinX.P.ZhangJ.Z.DongL.MaX.ZhangH.J.GaoB.L.Clinical and computed tomographic imaging features of novel coronavirus" exact="pneumonia" post="caused by SARS-CoV-2J. Infect.20208039440010.1016/j.jinf.2020.02.01732109443 78.ChenL.LiuH.G.LiuW.LiuJ.LiuK.ShangJ.DengY.WeiS.Analysis of clinical features of"/>
 <result pre="findings and temporal changes in patients with the novel coronavirus" exact="pneumonia" post="(2019-nCoV): A study of 63 patients in Wuhan, ChinaEur."/>
 <result pre="Wuhan, ChinaEur. Radiol.2020303306330910.1007/s00330-020-06731-x32055945 80.PanF.YeT.SunP.GuiS.LiangB.LiL.ZhengD.WangJ.HeskethR.L.YangL.et al.Time course of lung changes on" exact="chest" post="CT during recovery from 2019 novel coronavirus (COVID-19) pneumoniaRadiology202029571572110.1148/radiol.202020037032053470"/>
 <result pre="Infect. Dis.2020531689169910.2139/ssrn.3541136 85.ContiP.RonconiG.CaraffaA.GallengaC.E.RossR.FrydasI.KritasS.K.Induction of pro-inflammatory cytokines (IL-1 and IL-6) and" exact="lung inflammation" post="by Coronavirus-19 (COVID-19 or SARS-CoV-2): Anti-inflammatory strategiesJ. Biol. Regul."/>
 <result pre="patients with COVID-2019Nature202058146546932235945 87.PeirisJ.LaiS.PoonL.GuanY.YamL.LimW.NichollsJ.YeeW.YanW.CheungM.Coronavirus as a possible cause of severe" exact="acute" post="respiratory syndromeLancet20033611319132510.1016/S0140-6736(03)13077-212711465 88.ZhaoJ.YuanQ.WangH.LiuW.LiaoX.SuY.WangX.YuanJ.LiT.LiJ.Antibody responses to SARS-CoV-2 in patients of"/>
 <result pre="with COVID-2019Nature202058146546932235945 87.PeirisJ.LaiS.PoonL.GuanY.YamL.LimW.NichollsJ.YeeW.YanW.CheungM.Coronavirus as a possible cause of severe acute" exact="respiratory" post="syndromeLancet20033611319132510.1016/S0140-6736(03)13077-212711465 88.ZhaoJ.YuanQ.WangH.LiuW.LiaoX.SuY.WangX.YuanJ.LiT.LiJ.Antibody responses to SARS-CoV-2 in patients of novel"/>
 <result pre="syndromeLancet20033611319132510.1016/S0140-6736(03)13077-212711465 88.ZhaoJ.YuanQ.WangH.LiuW.LiaoX.SuY.WangX.YuanJ.LiT.LiJ.Antibody responses to SARS-CoV-2 in patients of novel coronavirus" exact="disease" post="2019Clin. Infect. Dis.202010.1093/cid/ciaa34432221519 89.ChenG.WuD.GuoW.CaoY.HuangD.WangH.WangT.ZhangX.ChenH.YuH.Clinical and immunological features of severe"/>
 <result pre="Dis.202010.1093/cid/ciaa34432221519 89.ChenG.WuD.GuoW.CaoY.HuangD.WangH.WangT.ZhangX.ChenH.YuH.Clinical and immunological features of severe and moderate coronavirus" exact="disease" post="2019J. Clin. Investig.202013010.1172/JCI13724432217835 90.GlassW.G.SubbaraoK.MurphyB.MurphyP.M.Mechanisms of host defense following severe"/>
 <result pre="disease 2019J. Clin. Investig.202013010.1172/JCI13724432217835 90.GlassW.G.SubbaraoK.MurphyB.MurphyP.M.Mechanisms of host defense following severe" exact="acute" post="respiratory syndrome-coronavirus (SARS-CoV) pulmonary infection of miceJ. Immunol.20041734030403910.4049/jimmunol.173.6.403015356152 91.HelmsJ.TacquardC.SeveracF.Leonard-LorantI.OhanaM.DelabrancheX.MerdjiH.Clere-JehlR.SchenckM.GandetF.F.High"/>
 <result pre="2019J. Clin. Investig.202013010.1172/JCI13724432217835 90.GlassW.G.SubbaraoK.MurphyB.MurphyP.M.Mechanisms of host defense following severe acute" exact="respiratory" post="syndrome-coronavirus (SARS-CoV) pulmonary infection of miceJ. Immunol.20041734030403910.4049/jimmunol.173.6.403015356152 91.HelmsJ.TacquardC.SeveracF.Leonard-LorantI.OhanaM.DelabrancheX.MerdjiH.Clere-JehlR.SchenckM.GandetF.F.High risk"/>
 <result pre="90.GlassW.G.SubbaraoK.MurphyB.MurphyP.M.Mechanisms of host defense following severe acute respiratory syndrome-coronavirus (SARS-CoV)" exact="pulmonary" post="infection of miceJ. Immunol.20041734030403910.4049/jimmunol.173.6.403015356152 91.HelmsJ.TacquardC.SeveracF.Leonard-LorantI.OhanaM.DelabrancheX.MerdjiH.Clere-JehlR.SchenckM.GandetF.F.High risk of thrombosis in"/>
 <result pre="of host defense following severe acute respiratory syndrome-coronavirus (SARS-CoV) pulmonary" exact="infection" post="of miceJ. Immunol.20041734030403910.4049/jimmunol.173.6.403015356152 91.HelmsJ.TacquardC.SeveracF.Leonard-LorantI.OhanaM.DelabrancheX.MerdjiH.Clere-JehlR.SchenckM.GandetF.F.High risk of thrombosis in patients"/>
 <result pre="syndrome-coronavirus (SARS-CoV) pulmonary infection of miceJ. Immunol.20041734030403910.4049/jimmunol.173.6.403015356152 91.HelmsJ.TacquardC.SeveracF.Leonard-LorantI.OhanaM.DelabrancheX.MerdjiH.Clere-JehlR.SchenckM.GandetF.F.High risk of" exact="thrombosis" post="in patients with severe SARS-CoV-2 infection: A multicenter prospective"/>
 <result pre="A nationwide analysis in chinaLancet Oncol.20202133533710.1016/S1470-2045(20)30096-632066541 93.CameronM.J.Bermejo-MartinJ.F.DaneshA.MullerM.P.KelvinD.J.Human immunopathogenesis of severe" exact="acute" post="respiratory syndrome (SARS)Virus Res.2008133131910.1016/j.virusres.2007.02.01417374415 94.PrompetcharaE.KetloyC.PalagaT.Immune responses in COVID-19 and"/>
 <result pre="nationwide analysis in chinaLancet Oncol.20202133533710.1016/S1470-2045(20)30096-632066541 93.CameronM.J.Bermejo-MartinJ.F.DaneshA.MullerM.P.KelvinD.J.Human immunopathogenesis of severe acute" exact="respiratory" post="syndrome (SARS)Virus Res.2008133131910.1016/j.virusres.2007.02.01417374415 94.PrompetcharaE.KetloyC.PalagaT.Immune responses in COVID-19 and potential"/>
 <result pre="analysis in chinaLancet Oncol.20202133533710.1016/S1470-2045(20)30096-632066541 93.CameronM.J.Bermejo-MartinJ.F.DaneshA.MullerM.P.KelvinD.J.Human immunopathogenesis of severe acute respiratory" exact="syndrome" post="(SARS)Virus Res.2008133131910.1016/j.virusres.2007.02.01417374415 94.PrompetcharaE.KetloyC.PalagaT.Immune responses in COVID-19 and potential vaccines:"/>
 <result pre="al.Longitudinal characteristics of lymphocyte responses and cytokine profiles in the" exact="peripheral" post="blood of SARS-CoV-2 infected patientsEBioMedicine20205510276310.1016/j.ebiom.2020.10276332361250 96.TetroJ.A.Is COVID-19 receiving ADE"/>
 <result pre="and its implications for therapyNat. Rev. Immunol.202022727310.1038/s41577-020-0308-332273594 99.LiX.ZaiJ.ZhaoQ.NieQ.LiY.FoleyB.T.ChaillonA.Evolutionary history, potential" exact="intermediate" post="animal host, and cross-species analyses of SARS-CoV-2J. Med. Virol.20209260261110.1002/jmv.2573132104911"/>
 <result pre="cats, dogs, and other domesticated animals to SARSâ€&quot;coronavirus 2Science20203681016102010.1126/science.abb701532269068 103.collab:" exact="American" post="Veterinary Medical Association (AVMA)SARS-CoV-2 in Animals, Including PetsAvailable online:"/>
 <result pre="104.CallawayE.Labs rush to study coronavirus in transgenic animalsâ€&quot;Some are in" exact="short" post="supplyNature202057918310.1038/d41586-020-00698-x 105.WentworthD.E.Gillim-RossL.EspinaN.BernardK.A.Mice susceptible to SARS coronavirusEmerg. Infect. Dis.2004101293129610.3201/eid1007.03111915324552 106.HoganR.J.GaoG.RoweT.BellP.FliederD.ParagasJ.KobingerG.P.WivelN.A.CrystalR.G.BoyerJ.et"/>
 <result pre="105.WentworthD.E.Gillim-RossL.EspinaN.BernardK.A.Mice susceptible to SARS coronavirusEmerg. Infect. Dis.2004101293129610.3201/eid1007.03111915324552 106.HoganR.J.GaoG.RoweT.BellP.FliederD.ParagasJ.KobingerG.P.WivelN.A.CrystalR.G.BoyerJ.et al.Resolution of" exact="primary" post="severe acute respiratory syndrome-associated coronavirus infection requires Stat1J. Virol.200478114161142110.1128/JVI.78.20.11416-11421.200415452265"/>
 <result pre="to SARS coronavirusEmerg. Infect. Dis.2004101293129610.3201/eid1007.03111915324552 106.HoganR.J.GaoG.RoweT.BellP.FliederD.ParagasJ.KobingerG.P.WivelN.A.CrystalR.G.BoyerJ.et al.Resolution of primary severe" exact="acute" post="respiratory syndrome-associated coronavirus infection requires Stat1J. Virol.200478114161142110.1128/JVI.78.20.11416-11421.200415452265 107.RobertsA.VogelL.GuarnerJ.HayesN.MurphyB.ZakiS.SubbaraoK.Severe acute"/>
 <result pre="SARS coronavirusEmerg. Infect. Dis.2004101293129610.3201/eid1007.03111915324552 106.HoganR.J.GaoG.RoweT.BellP.FliederD.ParagasJ.KobingerG.P.WivelN.A.CrystalR.G.BoyerJ.et al.Resolution of primary severe acute" exact="respiratory" post="syndrome-associated coronavirus infection requires Stat1J. Virol.200478114161142110.1128/JVI.78.20.11416-11421.200415452265 107.RobertsA.VogelL.GuarnerJ.HayesN.MurphyB.ZakiS.SubbaraoK.Severe acute respiratory"/>
 <result pre="Dis.2004101293129610.3201/eid1007.03111915324552 106.HoganR.J.GaoG.RoweT.BellP.FliederD.ParagasJ.KobingerG.P.WivelN.A.CrystalR.G.BoyerJ.et al.Resolution of primary severe acute respiratory syndrome-associated coronavirus" exact="infection" post="requires Stat1J. Virol.200478114161142110.1128/JVI.78.20.11416-11421.200415452265 107.RobertsA.VogelL.GuarnerJ.HayesN.MurphyB.ZakiS.SubbaraoK.Severe acute respiratory syndrome coronavirus infection"/>
 <result pre="severe acute respiratory syndrome-associated coronavirus infection requires Stat1J. Virol.200478114161142110.1128/JVI.78.20.11416-11421.200415452265 107.RobertsA.VogelL.GuarnerJ.HayesN.MurphyB.ZakiS.SubbaraoK.Severe" exact="acute" post="respiratory syndrome coronavirus infection of golden Syrian hamstersJ. Virol.20057950351110.1128/JVI.79.1.503-511.200515596843"/>
 <result pre="acute respiratory syndrome-associated coronavirus infection requires Stat1J. Virol.200478114161142110.1128/JVI.78.20.11416-11421.200415452265 107.RobertsA.VogelL.GuarnerJ.HayesN.MurphyB.ZakiS.SubbaraoK.Severe acute" exact="respiratory" post="syndrome coronavirus infection of golden Syrian hamstersJ. Virol.20057950351110.1128/JVI.79.1.503-511.200515596843 108.KimY.-I.KimS.-G.KimS.-M.KimE.-H.ParkS.-J.YuK.-M.ChangJ.-H.KimE.J.LeeS.CaselM.A.B.et"/>
 <result pre="respiratory syndrome-associated coronavirus infection requires Stat1J. Virol.200478114161142110.1128/JVI.78.20.11416-11421.200415452265 107.RobertsA.VogelL.GuarnerJ.HayesN.MurphyB.ZakiS.SubbaraoK.Severe acute respiratory" exact="syndrome" post="coronavirus infection of golden Syrian hamstersJ. Virol.20057950351110.1128/JVI.79.1.503-511.200515596843 108.KimY.-I.KimS.-G.KimS.-M.KimE.-H.ParkS.-J.YuK.-M.ChangJ.-H.KimE.J.LeeS.CaselM.A.B.et al.Infection"/>
 <result pre="coronavirus infection requires Stat1J. Virol.200478114161142110.1128/JVI.78.20.11416-11421.200415452265 107.RobertsA.VogelL.GuarnerJ.HayesN.MurphyB.ZakiS.SubbaraoK.Severe acute respiratory syndrome coronavirus" exact="infection" post="of golden Syrian hamstersJ. Virol.20057950351110.1128/JVI.79.1.503-511.200515596843 108.KimY.-I.KimS.-G.KimS.-M.KimE.-H.ParkS.-J.YuK.-M.ChangJ.-H.KimE.J.LeeS.CaselM.A.B.et al.Infection and rapid"/>
 <result pre="application of a rapid IGM-IGG combined antibody test for SARS-CoV-2" exact="infection" post="diagnosisJ. Med. Virol.202010.1002/jmv.2572732104917 114.ZhengJ.SARS-CoV-2: An emerging coronavirus that causes"/>
 <result pre="health monitoring and managementHealthcare202084610.3390/healthcare8010046 118.LiL.QinL.XuZ.YinY.WangX.KongB.BaiJ.LuY.FangZ.SongQ.Artificial intelligence distinguishes COVID-19 from community" exact="acquired" post="pneumonia on chest CTRadiology202010.1148/radiol.2020200905 119.SantoshK.AI-driven tools for coronavirus outbreak:"/>
 <result pre="monitoring and managementHealthcare202084610.3390/healthcare8010046 118.LiL.QinL.XuZ.YinY.WangX.KongB.BaiJ.LuY.FangZ.SongQ.Artificial intelligence distinguishes COVID-19 from community acquired" exact="pneumonia" post="on chest CTRadiology202010.1148/radiol.2020200905 119.SantoshK.AI-driven tools for coronavirus outbreak: Need"/>
 <result pre="managementHealthcare202084610.3390/healthcare8010046 118.LiL.QinL.XuZ.YinY.WangX.KongB.BaiJ.LuY.FangZ.SongQ.Artificial intelligence distinguishes COVID-19 from community acquired pneumonia on" exact="chest" post="CTRadiology202010.1148/radiol.2020200905 119.SantoshK.AI-driven tools for coronavirus outbreak: Need of active"/>
 <result pre="Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis SARS CoV-2" exact="Infection" post="(COVID-19)Available online: https://clinicaltrials.gov/ct2/show/NCT04283461(accessed on 10 April 2020) 123.Chinese Clinical"/>
 <result pre="for new enemy: Drug repurposing for treatment of newly emerging" exact="viral" post="diseasesVirol. Sin.202010.1007/s12250-020-00204-732048130 125.MifsudE.J.HaydenF.G.HurtA.C.Antivirals targeting the polymerase complex of influenza"/>
 <result pre="review of recent advances using tocilizumab in the treatment of" exact="rheumatic" post="diseasesRheumatol. Ther.20185214210.1007/s40744-018-0102-x29502236 132.AdhikariS.P.MengS.WuY.J.MaoY.P.YeR.X.WangQ.Z.SunC.SylviaS.RozelleS.RaatH.et al.Epidemiology, causes, clinical manifestation and diagnosis,"/>
 <result pre="causes, clinical manifestation and diagnosis, prevention and control of coronavirus" exact="disease" post="(COVID-19) during the early outbreak period: A scoping reviewInfect."/>
 <result pre="and Distributing the Work Plan for Prevention and Control of" exact="Pneumonia" post="Caused by Novel Coronavirus Infection in the Near FutureAvailable"/>
 <result pre="for Prevention and Control of Pneumonia Caused by Novel Coronavirus" exact="Infection" post="in the Near FutureAvailable online: http://www.nhc.gov.cn/tigs/s7848/202001/808bbf75e5ce415aa19f74c78ddc653f.shtml(accessed on 11 April"/>
 <result pre="of China (NHC)Notice on Prevention and Control of Novel Coronavirus" exact="Infection" post="Pneumonia in the Elderly PeopleAvailable online: http://www.nhc.gov.cn/lljks/tggg/202001/96e82ba8a14d41b283da990d39771493.shtml(accessed on 31"/>
 <result pre="China (NHC)Notice on Prevention and Control of Novel Coronavirus Infection" exact="Pneumonia" post="in the Elderly PeopleAvailable online: http://www.nhc.gov.cn/lljks/tggg/202001/96e82ba8a14d41b283da990d39771493.shtml(accessed on 31 January"/>
 <result pre="Republic of China (NHC)Notice on Further Prevention and Control of" exact="Pneumonia" post="Caused by Novel Coronavirus Infection in Rural AreasAvailable online:"/>
 <result pre="Further Prevention and Control of Pneumonia Caused by Novel Coronavirus" exact="Infection" post="in Rural AreasAvailable online: http://www.nhc.gov.cn/jkj/s3578/202001/f8d45f6af1d24ef18151c1d91cf8a028.shtml(accessed on 31 January 2020)"/>
 <result pre="and their inactivation with biocidal agentsJ. Hosp. Infect.2020114610.1016/j.jhin.2020.01.02232035997 140.MurdochD.R.FrenchN.P.COVID-19: Another" exact="infectious disease" post="emerging at the animal-human interfaceN. Z. Med. J.20201331215 141.MalikY.S.SircarS.BhatS.VinodhkumarO.R.TiwariR.SahR.RabaanA.A.Rodriguez-MoralesA.J.DhamaK.Emerging"/>
 <result pre="their inactivation with biocidal agentsJ. Hosp. Infect.2020114610.1016/j.jhin.2020.01.02232035997 140.MurdochD.R.FrenchN.P.COVID-19: Another infectious" exact="disease" post="emerging at the animal-human interfaceN. Z. Med. J.20201331215 141.MalikY.S.SircarS.BhatS.VinodhkumarO.R.TiwariR.SahR.RabaanA.A.Rodriguez-MoralesA.J.DhamaK.Emerging"/>
 <result pre="emerging at the animal-human interfaceN. Z. Med. J.20201331215 141.MalikY.S.SircarS.BhatS.VinodhkumarO.R.TiwariR.SahR.RabaanA.A.Rodriguez-MoralesA.J.DhamaK.Emerging coronavirus" exact="disease" post="(COVID-19), a pandemic public health emergency with animal linkages:"/>
 <result pre="of geographical information system (GIS); an advanced tracking tool for" exact="disease" post="surveillance and monitoring in veterinary epidemiologyAdv. Animal Vet. Sci.201311424"/>
 <result pre="epidemiologyAdv. Animal Vet. Sci.201311424 145.collab: World Health Organization (WHO)Battle against" exact="Respiratory" post="Viruses (BRaVe) InitiativeAvailable online: https://www.who.int/influenza/patient_care/clinical/brave/en/(accessed on 19 April 2020)"/>
 <result pre="therapies to counter Ebola virusFront. Immunol.20189180310.3389/fimmu.2018.0180330147687 153.ChatterjeeP.NagiN.AgarwalA.DasB.BanerjeeS.SarkarS.GuptaN.GangakhedkarR.R.The 2019 novel coronavirus" exact="disease" post="(COVID-19) pandemic: A review of the current evidenceIndian J."/>
 <result pre="154.ContiP.GallengaC.E.TetÃ¨G.CaraffaA.RonconiG.YounesA.ToniatoE.RossR.KritasS.K.How to reduce the likelihood of coronavirus-19 (CoV-19 or SARS-CoV-2)" exact="infection" post="and lung inflammation mediated by IL-1J. Biol. Regul. Homeost."/>
 <result pre="reduce the likelihood of coronavirus-19 (CoV-19 or SARS-CoV-2) infection and" exact="lung inflammation" post="mediated by IL-1J. Biol. Regul. Homeost. Agents.20203410.23812/Editorial-Conti-2 155.El ZowalatyM.E.JÃ¤rhultJ.D.From"/>
 <result pre="(pdb: 3KBH). (F) The superimposition of the RBDs of porcine" exact="respiratory" post="CoV (pdb: 4F5C) on HCoV-NL63 (pdb: 3KBH). RMSD: Root"/>
 <result pre="regions have been described by the WHO where the COVID-19" exact="disease" post="is present and are depicted on the map along"/>
 <result pre="civet cats Bats, camel Seafood, bats, pangolin (proposed) Transmission Animalâ€&quot;humanHumanâ€&quot;humanZoonotic" exact="disease" post="Animalâ€&quot;humanHumanâ€&quot;humanZoonotic disease Animalâ€&quot;humanHumanâ€&quot;humanHumanâ€&quot;animalZoonotic disease Speed of spread Moderate Low"/>
 <result pre="Bats, camel Seafood, bats, pangolin (proposed) Transmission Animalâ€&quot;humanHumanâ€&quot;humanZoonotic disease Animalâ€&quot;humanHumanâ€&quot;humanZoonotic" exact="disease" post="Animalâ€&quot;humanHumanâ€&quot;humanHumanâ€&quot;animalZoonotic disease Speed of spread Moderate Low High Seasonal"/>
 <result pre="Seafood, bats, pangolin (proposed) Transmission Animalâ€&quot;humanHumanâ€&quot;humanZoonotic disease Animalâ€&quot;humanHumanâ€&quot;humanZoonotic disease Animalâ€&quot;humanHumanâ€&quot;humanHumanâ€&quot;animalZoonotic" exact="disease" post="Speed of spread Moderate Low High Seasonal occurrence Winter"/>
 <result pre="and present status 5 July 2003 18 February 2020(Ongoing) Ongoing" exact="Total" post="number of cases 8422 2496 1,434,426 as of 8"/>
 <result pre="(subgenusâ€&quot;Sarbecovirus). CoVs Strain Name/Accession Number % Nucleotide Sequence Identity %" exact="Protein" post="Sequence Identity (a)Whole Genome-Based Comparison (29.9kb) South Korea SNU01/MT039890"/>
 <result pre="from regulatory bodies. Company Assay Targets Regulatory Status Centers for" exact="Disease" post="Control and Prevention (CDC) CDC 2019-nCoV Real-Time RT-PCR Diagnostic"/>
 <result pre="SARS-CoV-2 ORF1ab, E gene, RNase P (control) USA FDA-EUA Thermo" exact="Fisher" post="Scientific, Inc. TaqPath COVID-19 Combo Kit ORF1ab, N gene,"/>
 <result pre="vector and expressing synthetic minigene based on domains of selected" exact="viral" post="proteins Pathogen-specific aAPC Shenzhen Geno-Immune Medical Institute Phase I"/>
 <result pre="vector and expressing synthetic minigene based on domains of selected" exact="viral" post="proteins Drug candidates Favilavir Hisun Pharmaceutical, China Approved by"/>
 <result pre="Clinical trials are under progress Developed for treatment of Ebola" exact="virus infection" post="Lopinavir + Ritonavir AbbVie, USA Further research is under"/>
 <result pre="trials are under progress Developed for treatment of Ebola virus" exact="infection" post="Lopinavir + Ritonavir AbbVie, USA Further research is under"/>
 <result pre="USA Further research is under process Developed to treat HIV-1" exact="infections" post=""/>
</results>
